Enhancers of cellular cannibalism for use to sensitize tumors to radiation therapy
申请人:Institut Gustave-Roussy
公开号:US11471463B2
公开(公告)日:2022-10-18
The present invention is drawn to the use of the compounds highlighted in Tables 1 & 2 and analogs thereof, for enhancing IR-mediated cellular cannibalism in cancer cells. Said compounds are herein called “enhancers of IR-mediated cellular cannibalism”. They can be used to enhance tumor immunogenicity and/or to induce a significant protective anticancer immune response in subjects that will receive or that have received a radiotherapy treatment. In other words, said compounds can be used to potentiate a radiotherapy treatment in a subject in need thereof. Said compounds are preferably chosen in the group consisting of: Mebhydroline 1,5-napthalene disulfonate salt, Flurbiprofen, Minaprine dihydrochloride, Myricetin, Digoxin, Digitoxin, Lanatoside, LOPA87, VP331, RN-1-026, SG6163F, VP450, and VP43.
本发明涉及表 1 和表 2 所示化合物及其类似物在增强红外介导的癌细胞吞噬功能方面的用途。上述化合物在此称为 "红外介导的细胞吞噬作用增强剂"。它们可用于增强肿瘤免疫原性和/或诱导即将接受或已经接受放疗的受试者产生显著的保护性抗癌免疫反应。换句话说,上述化合物可用于增强需要接受放疗的受试者的放疗效果。所述化合物最好选自以下组别1,5-萘二磺酸甲羟戊酸盐、氟比洛芬、盐酸米那普林、米利西汀、地高辛、地高辛、拉那托苷、LOPA87、VP331、RN-1-026、SG6163F、VP450 和 VP43。